48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical can

Sac-TMT is a TROP2-directed ADC with a unique, bifunctional linker that maximizes payload delivery to tumor cells. In a prior phase II study, sac-TMT + pembro had promising antitumor activity (ORR, 58% [22/38]) in participants (pts) with recurrent or metastatic cervical cancer that progressed on/after platinum-doublet chemo. TroFuse-036/GOG-3123/ENGOT-cx22 (NCT07216703) is evaluating 1L maintenance sac-TMT + pembro ± bev vs SoC in pts with cervical cancer.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108073
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical can

V. Desai, K. Hasegawa, L. Barraclough, A.C. de Melo et al.
ESMO Open
Cancer Immunotherapy and Biomarkers
article

48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical can

V. Desai, K. Hasegawa, L. Barraclough, A.C. de Melo, B.M. Slomovitz, D. Cibula, K.S. Tewari, T. van Gorp, A. Farolfi, L. Fariñas Madrid, C. Dubot, JY Lee, C. Tekin, I.A. Casarini, Z. Yu, A. Ferrero, N. Cloven, F. Contreras Mejia, B.J. Monk, S. Gupta
article en

Abstract

Sac-TMT is a TROP2-directed ADC with a unique, bifunctional linker that maximizes payload delivery to tumor cells. In a prior phase II study, sac-TMT + pembro had promising antitumor activity (ORR, 58% [22/38]) in participants (pts) with recurrent or metastatic cervical cancer that progressed on/after platinum-doublet chemo. TroFuse-036/GOG-3123/ENGOT-cx22 (NCT07216703) is evaluating 1L maintenance sac-TMT + pembro ± bev vs SoC in pts with cervical cancer.

ESMO OpenVol. 11
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), National University of Mar del Plata (AR), Yonsei University (KR), Homi Bhabha National Institute (IN), University of California, Irvine (US), Charles University (CZ), Severance Hospital (KR), Tata Memorial Hospital (IN), Texas Oncology (US), Mount Sinai Medical Center (US), University of California, Irvine Medical Center (US), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Centre François Baclesse (LU), Florida Cancer Specialists & Research Institute (US), Instituto Nacional de Cancerología (CO), Centre François Baclesse (FR), Vall d'Hebron Hospital Universitari (ES), A. O. Ordine Mauriziano di Torino (IT), The Christie NHS Foundation Trust (GB), Instituto Nacional de Câncer - INCA (BR), Gangnam Severance Hospital (KR), Yonsei University Health System (KR), General University Hospital in Prague (CZ), Vall d'Hebron Institute of Oncology (ES), Saitama Medical University (JP), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 8%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.